India Pharma Exports Near $29B: Growth & Projections
Key Highlights
India’s pharma exports approach $29 billion, a 5% increase. The sector is projected to reach $130 billion by 2030. Learn about India’s pharma growth.
India’s pharmaceutical sector continues its robust growth trajectory, with exports nearing $29 billion by February of this financial year. This represents a 5% increase, underscoring the sector’s resilience amid global economic headwinds.
The Indian pharmaceutical industry, currently valued at approximately $60 billion, is projected to reach $130 billion by 2030. This ambitious target reflects the sector’s strategic importance to the Indian economy and its increasing role in global healthcare supply chains.
Despite facing various challenges, including supply chain disruptions and pricing pressures, Indian pharmaceutical companies have maintained a steady growth rate. This growth is attributed to a combination of factors, including increased investment in research and development, a focus on generic drug manufacturing, and strategic partnerships with international players.
The sector’s expansion is also supported by favorable government policies aimed at promoting domestic manufacturing and exports. Initiatives such as the Production Linked Incentive (PLI) scheme have incentivized companies to invest in expanding their production capabilities and enhancing their global competitiveness.
Looking ahead, the Indian pharmaceutical industry is expected to continue its growth momentum, driven by increasing demand for affordable medicines, a growing middle-class population, and expanding healthcare infrastructure. However, companies will need to navigate evolving regulatory landscapes and intensifying competition to sustain their growth trajectory.
The projected growth to $130 billion by 2030 positions India as a key player in the global pharmaceutical market, attracting further investment and innovation to the sector.